Valuation dashboard for Tenaya Therapeutics, Inc. (TNYA) with P/E N/A, P/B 2.05, EV/EBITDA -0.77 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small mol...
Analysis Summary
Trailing-twelve-month margins: gross margin 263.7%, operating margin -79.3%, net margin -77.2%.
At the current price of $0.66, TNYA has negative trailing earnings (P/E not meaningful) and an ROE of -108.05%. Market capitalisation stands at $143M.
Balance sheet quality for TNYA: current ratio of 6.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.05 |
| EV / EBITDA | -0.77 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TNYA | Tenaya Therapeutics, Inc. | $143M | 2.05 | -108.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.66 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -108.05% |
| Return on Invested Capital | -136.78% |
| Return on Assets | -110.24% |
| Gross Margin | 263.67% |
| Operating Margin | -7929.89% |
| Net Margin | -7723.97% |
Related companies: ABEO · CRBU · ENTA · FHTX · HUMA · IMRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of TNYA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks